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Genetic haemochromatosis: diagnosis and treatment
Abstract
Genetic  haemochromatosis  (GH)  is  the  most  common  inherited  genetic  disorder  in
caucasians, affecting approximately 1 in every 200–250 people. It  leads to an increased
absorption and deposition of iron, and if it is untreated it can cause systemic iron overload in
some patients. This iron overload can cause inflammation and tissue damage to multiple
organs, with the potential to lead to heart disease, diabetes and cirrhosis of the liver. Despite
being a common condition, it is purported as being under diagnosed. However, it is known
that some patients with a diagnosis of GH will present with cirrhosis at a young age, while
others are virtually asymptomatic.
Symptoms can be generalised, and diagnosis is made on blood tests. Treatment for GH
requires  the  removal  of  blood,  known  as  venesection.  Approximately  400–500mls  are
removed at a time, and this procedure can be undertaken weekly until  ferritin levels are
brought down to 50 µg/l or below.
Key words
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Overview
Genetic  haemochromatosis  (GH)  is  the  most  common  inherited  genetic  disorder  in
caucasians  (Bacon  et  al,  2011).  It  has  a  worldwide  distribution  but  commonly  affects
Northern Europeans, especially those of Celtic or Nordic descent, at a ratio of approximately
1 in 220–250 people (Adams et al, 2005; Phatak et al, 2008). However, the British Liver
Trust (BLT) (2016) and The Haemochromatosis Society (HS) (2016a) believe the proportion
of people diagnosed with this condition in Britain and Ireland to be higher—approximately 1
in 200. Despite GH being the most common genetic disorder, it is suggested that only 1 in
every 5000 people are diagnosed with GH, making it an under diagnosed condition (BLT,
2016).
Although iron is required for the formation of red blood cells and assists with the transport
of oxygen within the cells, GH causes the body to absorb more iron from the diet than it
requires. As the liver is the main storage for iron, any excess is transported there (Powell et
al, 2016). Over time, GH can cause systemic iron overload, not only within the liver, but also
in  other  internal  organs,  such  as  the  pancreas,  heart  and  joints,  eventually  causing
inflammation  and  tissue  damage,  which  can  lead  to  heart  disease  and  diabetes.  Liver
disease usually precedes disease in other affected organs (Ulvik 2015), and it can lead to
the development of cirrhosis, with the associated complications of varices and hepatocellular
carcinoma. However, this only occurs in some, not all, patients diagnosed with GH, and it is
assumed to be dependent on factors including genetics, gender, alcohol consumption and
menstruation  or  blood  loss  (Powell  et  al,  2016).  GH appears  to  affect  more  men than
women, and this could be explained, in part by menstruation in females with other potential
causes yet to be explained. 
The symptoms of haemochromatosis are often non-specific (Table 1), and it is only when
the disease reaches an advanced stage,  which can take many years,  that  clinical  signs
become apparent (Bacon et al, 2011). 
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Table 1. Haemochromatosis symptoms
Fatigue
Arthralgia (joints pain), especially in the knuckles of the 
first two fingers
Abdominal pain
Limb weakness
Bronzing of the skin pigmentation (in association with type 
2 diabetes)
Loss of libido
Possible impotence or early menopause
Type 2 diabetes
Cardiomyopathy
Fibrosis or cirrhosis of the liver 
Hepatomegaly (oversized liver)
Varices
Source: British Liver Trust (2016)
Diagnosis
Abnormally high levels of iron are often the only sign of haemochromatosis, and therefore
diagnosis is made on the basis of blood tests (Figure 1). 
Figure 1. Diagnosing iron overload
Serum ferritin 
Iron is stored as a protein called ferritin, and a ferritin level can give an indication of the
body’s  iron  store.  The  highest  concentrations  of  ferritin  are  found  in  hepatocytes  and
reticuloendothelial cells (Nall, 2017). When more iron is required, the body will signal the
cells to release ferritin. At this point ferritin binds to another protein called transferrin, which
transports the ferritin to where it is required.
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Normal levels of ferritin are up to 300µg/L in men and post-menopausal women and up
200µg/L in younger females (HS, 2017). People with GH are born with normal ferritin levels,
but over time the loading of iron stores will  eventually increase the ferritin levels. Raised
ferritin (hyperferritinaemia) is indicative of GH, but alone it is not sufficient for a diagnosis, as
ferritin levels can also be raised by inflammatory or metabolic conditions, such as excessive
alcohol consumption and diabetes (Torti and Torti, 2002; European Association for the Study
of the Liver (EASL) 2010).
Transferrin saturation
Transferrin saturation (TS) is the ratio of serum iron to iron binding capacity expressed a
percentage that  indicates how much iron is available for use. It is calculated by measuring
serum iron and dividing it  by total iron binding capacity (HS, 2016). If  a TS blood test is
requested, for an accurate result, patients should be advised to fast overnight and take the
blood tests prior to eating breakfast, as iron levels can vary throughout the day. A normal TS
is  around  30%,  and  it  is  slightly  higher  in  men  than  in  women.  A TS  of  over  50% is
suggestive of iron overload and less than 20% indicates iron deficiency. If on two occasions
the TS test result is over 50% in men or 45% in women, iron overload is present , a HFE
gene test should be requested to establish whether there is a genetic cause.
HFE gene test 
The most common cause of iron overload is GH, which can be diagnosed or ruled out
with an HFE gene test. This is a relatively recent option, first described by Feder et al (1996).
HFE stands for high (H) iron (FE) and is not an abbreviation for haemochromatosis.
There are two common genetic  mutations associated with iron overload—C282Y and
H63D (the numbers representing where the mutations are found on the gene) (BLT, 2017).
As GH is an autosomal recessive disorder, it only develops in homozygotes, those who have
inherited two copies of the same abnormal gene, one from each parent (Bacon et al, 2011).
Heterozygotes,  those who inherit  only one copy of the gene,  act as carriers but  will  not
develop iron overload.
According to Powell et al (2016), around one in ten of Northern Europeans (one in eight in
the UK) are C282Y heterozygotes (HS, 2016; BLT, 2017). Therefore, around 1 in 200 people
Northern Europeans will be C282Y homozygotes, with the associated risk of iron overload.
The H63D mutation is associated with milder disease than C282Y, but H63D homozygotes
can occasionally develop iron overload (White et al, 2011). It is possible for an individual to
have one copy of H63D gene and one copy of the C282Y mutation, known as a being a
compound heterozygote; this can lead to iron overload, but not to the same extent as C282Y
homozygotes.
Homozygotes of  either  mutation  will  pass on one copy of  the gene to their  children,
whereas heterozygotes may or may not pass their gene. The possibility of iron overload only
arises in heterozygotes if a carrier has children with another carrier, then their children may
be at risk of being a heterozygote carrier, a homozygote with a potential to develop iron
overload later in life or a compound heterozygote (Table 2).
A symptomatic patient shown by an HFE gene test to be a C282Y or H63D homozygote
or a H63D–C282Y heterozygote may be diagnosed with GH.
Table 2. HFE example gene mutations and iron overload
Parent 1 Parent 2 Probability of child
Homozygote Homozygote Homozygote 100%
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Homozygote Heterozygote Homozygote 50%
Heterozygote 50%
Heterozygote Heterozygote Homozygote 25%
Heterozygote 50%
Normal 25%
Normal Homozygote Heterozygote 100%
Normal Heterozygote Heterozygote 50%
Normal 50%
Compound 
heterozygote
Compound 
heterozygote
Homozygote 50% (each gene 25%)
Compound heterozygote 50%
Other genetic links 
Should the HFE gene test results be negative, there are a number of other less common 
genetic mutations linked to biochemical or clinical iron overload. Research links these genes 
to a common metabolic pathway that involves the production of hepcidin, a peptide hormone
secreted by the liver that regulates iron levels (Table 3).
Secondary iron overload
However,  if  a  genetic  link  is  ruled  out  entirely,  this  is  referred  to  as  secondary  iron
overload and may have a number of causes, some related to other conditions and some
arising from excessive oral or parenteral intake of iron (Table 3). Many of these, such as
juvenile and neonatal haemochromatosis, are extremely rare (BLT, 2017).
Table 3. Iron overload disorders
Genetic haemochromatosis
HFE-related C282T homozygote
Compound heterozygote
Other HFE mutations
Non-HFE gene related Haemojuvelin
Transferrin receptor 2
Ferroportin
Hepcidin
African iron overload
Secondary iron overload
Iron loading anaemias Thalassemia major
Sideroblastic
Chronic haemolytic anaemia
Aplastic anaemia
Pyruvate kinase deficiency
Pyridoxine responsive anaemia
Parenteral iron overload Red blood cell transfusions
Iron injections
Long term haemodialysis
Chronic liver disease Hepatitis C
Hepatitis B
Alcohol related liver disease
Non-alcoholic liver disease
Following portal-caval shunt
Porphyria cutanea tarda
Miscellaneous Neonatal iron overload
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Aceruloplasminaemia
Congenital atransferrinaemia
Source: Bacon et al (2011)
Family screening
The genetic  nature of  a GH diagnosis can have serious implications not  only  for  the
patient  but  for  his  or  her  immediate  family,  including  siblings  and  children.  Any  patient
diagnosed  with  GH should  be  provided  with  an  information  letter  to  distribute  to  family
members to inform them of the diagnosis (Figure 1). Siblings of a patient diagnosed with GH
have a 25% chance of being homozygotes themselves. If children or siblings of someone
diagnosed with GH are younger than the age of consent, the other parent can also have a
HFE gene test, and the results can be compared to assess the probability of their child’s
genetic predisposition (Scott and Lawson, 2015). Iron studies may be preferable to genetic
testing in younger family members, considering the potential impact of being labelled with a
genetic disorder that might be poorly understood.
Impact assessment
Patients diagnosed with GH should be referred to secondary care for treatment and follow
up by gastroenterology/hepatology, or in some instances haematology, departments.
Liver function tests (LFTs) should be carried out to assess for signs of liver damage,
including  raised  levels  of  the  liver  transaminases  alanine  aminotransferase  (ALT)  and
aspartate aminotransferase (AST). The ferritin level should be consulted and the size of the
liver  should  be  checked  for  hepatomegaly.  A liver  biopsy  to  assess  the  extent  of  liver
damage (fibrosis or cirrhosis) should be requested if any of the following conditions are met:
 Serum ferritin 1000 µg/L or greater
 Elevated liver function tests such as (ALT or AST)
 Hepatomegaly (EASL, 2010).
Should liver biopsy be contraindicated in patients with hyperferritinaemia when HFE gene
has not  been detected,  hepatic  iron  levels  can be estimated using magnetic  resonance
imaging (MRI).
Treatment 
Venesection
There  is  no  known  cure  for  GH,  but  it  can  be  effectively  treated  by  removing  iron-
saturated blood from the body in a procedure known as venesection (Figure 2). This must be
carried  out  regularly,  typically  once  a  week  in  the  induction  phase  and  1–3  monthly
afterwards, and can continue indefinitely throughout a patient’s life. Venesection is typically
carried out in a hospital day unit, and approximately 400–500ml of blood will be removed
each session. 
Once  venesection  has  commenced,  some  symptoms,  including  abdominal  pain  and
fatigue may improve, whereas other serious symptoms, such as diabetes, sexual problems
and arthritis,  are unlikely to get better.  This can also depend on the stage at  which the
disease was diagnosed.
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Figure 2. Equipment used for venesection
Consent
Before patients can give their informed consent to begin venesection, they must be given
a serious, thorough and thoughtful explanation of the impact of venesection and the risks
associated with phlebotomy. There are potential negative consequences for health, including
problems with venous access and potential damage to veins (Adams and Barton, 2010). The
most serious risk, although it is extremely rare, is damage to the ulna nerve, and there are
more  frequent  minor  risks,  such  as  bruising,  discomfort  and  the  possibility  of  inducing
anaemia. On top of this, this weekly commitment inevitably has a significant impact in terms
of time and resources on the patients’ life. This is especially so if there is a long wait, the day
unit is difficult to access or appointments are not available at a convenient time, and the
cumulative cost of travel, parking and/or lost working hours can be considerable. 
Ferritin monitoring
For every venesection appointment, blood samples should be taken to accurately monitor
haemoglobin and ferritin levels. These samples can be taken either a day or two prior to
venesection or just as venesection is commenced, using a specially adapted bag, to save
the patient  exposure to another needle puncture. The samples are used to estimate the
ferritin level once the unit of blood has been removed, which helps guide the frequency of
return venesection visits (Table 4). Although a normal ferritin level can be up to 200–300µg,
in  GH it  can  be in  the  thousands.  In  such  cases,  it  can  take  many  months  of  weekly
venesections to bring the ferritin level down to a healthy 50µg/l (Table 4).
On occasion, frequent venesections can lower patients’ serum ferritin so much that they
become anaemic. In these cases, it is not recommended to prescribe oral iron supplements;
instead, it is treated by postponing venesection until ferritin levels rise back to around 50
µg/L (Table 4). If, despite halting regular venesections, ferritin levels fail to rise, then another
cause for  the drop in ferritin and/or haemoglobin should be considered;  this can involve
checking: 
 Haematinics (Table 5)
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 Stool samples for faecal occult blood
 Colonoscopy for gastrointestinal bleeding.
Table 4. Venesection process
Phase Ferritin level Venesection frequency
Induction Significantly above 50µg/l Weekly 
Maintenance Around 50µg/l Every 1–3 months
Remedial Below 20µg/l (or haemoglobin level 
below 10) on two consecutive visits
Every 4–6 months
Remedial Above 50 on two consecutive visits Every 2 months 
Source: Scott and Lawson (2012)
Table 5. Haematinic panel
Blood test
Full blood count
Ferritin (iron store)
Transferrin saturation 
B12/cobalamin (deficiency can mean pernicious anaemia)
B9/folate (required for the formation of red blood cells)
Coombe’s test (for antibodies that may indicate haemolytic anaemia)
Blood film
Liver monitoring
Patients undergoing venesection for GH may require regular follow up in the hepatology
clinic to monitor for varices and hepatocellular carcinoma. This is especially recommended if
a patient also has:
 Fibrosis or cirrhosis
 Abnormal LFTs
 Hepatomegaly
 Serum ferritin of 1000µg/L or above
Cirrhosis is of particular concern, as it  carries a high risk of developing hepatocellular
carcinoma  (HCC) (Niederau  et  al,  1996).  Patients  with  GH and  cirrhosis  require  close
monitoring  with  6-monthly  ultrasound  scans  of  the  liver  and  6-monthly  alpha-fetoprotein
(AFP) blood tests (National Institute for  Health Care and Excellence (NICE),  2016).  Any
sudden deterioration in LFTs should prompt an urgent ultrasound scan request. 
Blood donation
Although large volumes of  perfectly healthy blood are removed by venesection in the
NHS, this blood is not automatically kept for donation and is often discarded. This is because
blood collection is founded on the principle of voluntary donation, and blood collected as a
medical necessity, as in venesection, is not given altruistically and cannot be automatically
collected as a donation (Venesection, 2010).
However, as blood from venesection is now accepted by blood services in the UK and
around the world (Pauwels et al, 2013; Marrow  B et al, 2015), patients without significant
comorbidities or cirrhosis entering the maintenance phase should be encouraged to become
regular  blood donors.  EASL (2010) guidelines advocate the use of  blood for  therapeutic
phlebotomy,  where  there  are  no  contraindications,  for  transfusion.  The  National  Blood
Service indicates patients with haemochromatosis can offer blood from venesection up to
every 6 weeks.  The ferritin level of  these blood donations should be monitored and the
results passed to their GP.
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Lifestyle advice
As well as attending for venesection, patients can help keep their ferritin levels down with
lifestyle changes.  Conditions known to raise  ferritin  and accentuate disease progression
include diabetes and alcohol consumption, so patients should be strongly advised to reduce
how  much  alcohol  they  drink  or  or,  if  possible,  stop  altogether  (Scotet  et  al,  2003).
Meanwhile, tannin can help prevent the absorption of some iron, and calcium can limit the
absorption of iron from the diet, so patients can be encouraged to drink tea with milk (BLT,
2016). Patients can also be recommended to avoid: 
 Iron-fortified foods, including some breakfast cereals
 Vitamin C, as it aids iron absorption
 Shellfish, as it can contain potentially fatal bacteria.
Conclusion
HE is a condition that requires long-term specialist care and monitoring, with treatment
tailored accordingly. Nurses, whether they are specialists, practitioners or just on the day
case units, are a key patient resource alongside the medical teams. They play an important
part  in  the  diagnosis,  treatment  and  especially  surveillance  of  iron  overload  and  GH.
Treatment  of  GH relies  heavily  on  nurses  to  manage regular  venesection.  Nurses  also
provide support for patients and their families, answering any questions as they arise and
minimising concerns. This holistic role can also involve emotional support; in the author’s
department,  the  nurses  often  hold  a  small  celebration  with  tea,  cake  and  balloons  for
patients who have had their 50th venesection.
More  information  can  be  obtained  about  this  condition  from  the  Haemochromatosis
Society and the British Liver Trust websites. Both organisations produce patient information
leaflets  with  accurate  disease-specific  information,  patient  support  groups  and  personal
venesection  records.  These  are  a  helpful  source  of  information  and  advice  to  support
patients to become more empowered and involved in self-management.
Throughout  2017,  the Haemochromatosis Society undertook a large patient  survey to
look at symptoms before and after treatment, as well patient experience of treatment and
possible links to other medical conditions (HS, 2017). This is the largest survey to date on
this topic, and nothing similar has been undertaken since 2004. A report on the findings is
expected in 2018, and this could lead to further medical research on this condition. 
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